Budesonide/Formoterol fumarate/Glycopyrronium Bromide

布地奈德/富马酸福莫特/格隆溴铵

Report date: 2026/05/22 20:01:29

Base Information

Drug NameBudesonide/Formoterol fumarate/Glycopyrronium Bromide
Drug Alias Name布地奈德/罗格隆溴铵/富马酸福莫特Budesonide/PT 003PT-003/budesonide富马酸福莫特/罗格隆溴铵/布地奈德LAMA/LABA/ICS triple combination - Pearl Therapeutics +[18] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionBeta-2 adrenergic receptor agonistsGlucocorticoid receptor agonistsMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptorBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsPulmonary Disease, Chronic Obstructive
Approved Indications in ChinaPulmonary Disease, Chronic Obstructive
Original Approved Country/TerritoryJapan
Original Approved Date2019/06/18
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsYes Formoterol FumarateBudesonideGlycopyrronium Bromide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdPearl Therapeutics IncAstrazeneca Dunkerque Production +[6] 
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeR03AL11
Related LinksKEGG